EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS

Abstract

Аbstract. Сlinical and immunocorrective efficiency of Roncoleukin® (IL-2) monotherapy applied as subcutaneous injections versus inhalatory mode of treatment, was studied in patients with chronic recurrent infections. It was shown that administration of Roncoleukin® at a total dose of 1.5 mg was accompanied by increased activity of Th1 lymphocytes and reduced in vitro production of IL-10, and does not exert any adverse immunotropic effects associated with Treg expansion. In general, the positive clinical effect was registered in 65% (26/40) of the patients, and its duration ranged between 3 and 7 months (a mean of 4.4±0.2 months). Clinical efficiency of Roncoleukin® inhalations proved to be not inferior to conventional Roncoleukin® immunotherapy performed by subcutaneous injections (resp., 70 and 60% of positive responses), and allows a more significant prolongation of event-free remission. (Med. Immunol., 2011, vol. 13, N 2-3, pp 227-236)

Keywords

• cytokine balance
• regulatory t-cells
• cytokine therapy
• il-2
• recurrent infections